Moreover, DHEAS is a poor biomarker of 21OHD control, which can be paradoxically low in poorly controlled classic 21OHD patients (12, 29). This evidence concerns the gene SULT2A1 and classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.